Home/ Stocks/ NGNE

Neurogene, Inc. Common Stock

NGNE XNAS

$20.90 +1.54 (+7.95%) ▲ 15-min delayed

Open

$19.40

High

$21.50

Low

$18.81

Volume

295.6K

Market Cap

$299.88M

About Neurogene, Inc. Common Stock

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 107 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-20,953,000	$-0.99
Q2 2025	$0	$-22,016,000	$-1.05
Q1 2025	$0	$-22,647,000	$-1.08
FY 2024	$925.0K	$-75,144,000	$-4.28

Related Market News

No specific coverage for NGNE yet. Check out our latest market news or earnings calendar.

Get NGNE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Neurogene, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.